DILTIAZEM HYDROCHLORIDE

Post-LOE

diltiazem hydrochloride

Molecular Devices

ANDAORALTABLET

Approved

Nov 1992

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTIAZEM HYDROCHLORIDE (diltiazem hydrochloride) by Molecular Devices is clinical pharmacology the therapeutic benefits achieved with diltiazem hydrochloride is believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for chronic stable angina, angina due to coronary artery spasm. First approved in 1992.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The therapeutic benefits achieved with diltiazem hydrochloride is believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Although precise mechanisms of its…

Worked on DILTIAZEM HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DILTIAZEM HYDROCHLORIDE

Mechanism of Action

Indications (2)